atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose bladder cancer more accurately than current standard methods.
Read full article here.
The UK's national research agency is backing a plan to speed up dementia testing with up to £80 million ($105.48 million) in funding, to improve diagnosis rates and cut waiting times that can exceed a year.
Read full article at Medscape…
Attendees
Sponsors and Exhibitors
Contact us